{"id":"NCT01290094","sponsor":"Hoffmann-La Roche","briefTitle":"A Study of Bonviva/Boniva (Ibandronate) in Biphosphonate-Na誰ve Women With Post-Menopausal Osteoporosis","officialTitle":"Interventional, Single Arm, Open Label Study of the Efficacy, Safety and Compliance to the Treatment With Intravenous (IV) Ibandronate (Bonviva速) in the Postmenopausal Osteoporosis Treatment of Bisphosphonates na誰ve Patients in Daily Practice","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2011-04","primaryCompletion":"2014-07","completion":"2014-07","firstPosted":"2011-02-04","resultsPosted":"2015-08-13","lastUpdate":"2015-08-13"},"enrollment":41,"design":{"allocation":"NON_RANDOMIZED","model":"SINGLE_GROUP","masking":"NONE","primaryPurpose":"TREATMENT"},"conditions":["Post Menopausal Osteoporosis"],"interventions":[{"type":"DRUG","name":"ibandronate [Bonviva/Boniva]","otherNames":[]}],"arms":[{"label":"Single Arm","type":"EXPERIMENTAL"}],"summary":"This single arm, open label study will assess the efficacy and safety of and compliance to treatment with Bonviva/Boniva (ibandronate) in biphosphonate-na誰ve patients with post-menopausal osteoporosis. Patients will receive Bonviva/Boniva at a dose of 3 mg intravenously every three months. Anticipated time on study treatment is 12 months with a follow-up of 12 months.","primaryOutcome":{"measure":"Percent Change From Baseline in Mean Lumbar Spine Bone Mineral Density (BMD) at Month 12","timeFrame":"Baseline, Month 12","effectByArm":[{"arm":"Ibandronate","deltaMin":5.67,"sd":7.86}],"pValues":[{"comp":"OG000","p":"<0.0005"}]},"eligibility":{"minAge":"50 Years","sex":"FEMALE","healthyVolunteers":false,"inclusionCount":4,"exclusionCount":3},"locations":{"siteCount":2,"countries":["Bosnia and Herzegovina"]},"refs":{"pmids":[],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":9,"n":40},"commonTop":["Flu like symptoms","Neuralgia","Gastrointestinal pain","Injection site reaction"]}}